SlideShare a Scribd company logo
DIABETES (+/- coronary artery disease)
   COLLABORATIVE FLOW SHEET/ ENCOUNTER FORM
                                                                                                                                                                          ♦ PATIENT NAME
         PAST HISTORY
                                  ALCOHOL OVERUSE                                                ARRHYTHMIA: ATRIAL FIB                 ARRHYTHMIA: OTHER
                                                                                                                                                                          ♦ HSN # (OR OTHER UNIQUE PATIENT ID)                        ♦ GENDER                 Male
                                  ARTHRITIS                                                      CANCER                                 CARDIOMYOPATHY                                                                                    Female        Undifferentiated
                                  CHF                                                            CHRONIC LUNG DIS.                      DEPRESSION                        ♦ PHONE (INCLUDE AREA CODE)                         ♦ BIRTHDATE (DD-MMM-YYYY)
                                  HYPERTENSION                                                   LIPID ABNORMALITY                      LIVER DYSFUNCTION
                                  OBESITY                                                        PERIPH. VASC. DIS.                     RENAL DYSFUNCTION
                                                                                                                                                                          CHART NUMBER                    PRACTICE NAME
                                  STROKE/TIA                                                     SUBSTANCE ABUSE                        VALVULAR HD
                                                                                                                                                                          ♦ PROVIDER NAME                                            PROVIDER ID # (MSP #)
         ♦ DIABETES                                                                 YEAR OF DX:                 TYPE 1         TYPE 2        OTHER

         ♦ CAD                                                                      ___CHRONIC ANGINA, YEAR OF DX:                                   ___MI, YEAR OF DX:                   ___CABG, DATE:                             FRAMINGHAM
                                                                                                                                                                                                                                     RISK
         ___                                                                        ___ACS/UNSTABLE ANGINA , YEAR OF DX:                             ___PCI/Stent. DATE:                                                             SCORE

    DIAGNOSTIC/ CLINICAL DATA, BY DATE                                                                                                                                                                     NEW DATA                                          √ = RECALL
    REVIEW                                                                                                       ♦ = MANDATORY                         MOST RECENT DATA
    FIELDS                                                                                                                                                                                                 DATE OF VISIT:
                                                           URGENT CARE for DM &/or CAD
                                                                                                                                                                                                               None                (enter # of urgent visits)
                                                           ER/hospitalizations since last planned visit
                                        CLINICAL STATUS




                                                                                  REVIEWED BLOOD GLUCOSE RECORDS                                                                                               REVIEWED
                                                          GLYCEMIC
                                                          CONTROL




                                                                                  ♦ A1C EVERY 3 MONTHS:                                                                                                    ENTER VALUE
                                                                                   TARGET ≤ 7.0%                                                                                                           DATE OF TEST
                                                                                  DIABETES MEDICATIONS/INSULIN
                                                                                                                                                                                                               REVIEWED                   ADJUSTED
                                                                                  Review & adjust PRN
                                                                                  SYMPTOMS STABLE: angina, palpitations,                                                                                      N/A         STABLE                 NOT STABLE
                                                             CAD




                                                                                  shortness of breath, swelling, dizziness                                                                                    angina      palp.  SOB              swelling dizzy
                                                           ♦ BLOOD PRESSURE                                                                                                                                ENTER VALUE
                                        HTN




                                                            TARGET ≤130/80                                                                                                                                 DATE OF TEST
     3 TO 6 MONTHS




                                                           TARGET BODY MASS INDEX (BMI)
                                                                                                                                                                                                                                     LBS           KG
                                                           18.5 – 24.9 Height: Enter weight (LBS or KG)
                                        LIFESTYLE




                                                                                                                                                                                                                                nd
                                                           ♦ SMOKING                                                                                                                                           Current         2     Hand          Past       Never
                                                           AEROBIC EXERCISE
                                                                                                                                                                                                               YES             NO                                     IA
                                                           > 30 minutes most days, moderate intensity
                                                           OTHER LIFESTYLE FACTORS
                                                                                                                                                                                                               REVIEWED
                                                           Stress, diet, alcohol
                                                                                                                                                                                                               YES
                                                          ♦ ANTI-PLATELET (ASA/OTHER)
                                                                                                                                                                                                               NO:       CI        NT       $      RF       DA       IA
                                                                                                                                                                                                               YES
                                                          ♦ ACE OR ARB
                                        MEDICATIONS




                                                                                                                                                                                                               NO:       CI        NT       $      RF       DA       IA
                                                                                                                                                                                                               YES
                                                          ♦ STATIN
                                                                                                                                                                                                               NO:       CI        NT       $      RF       DA       IA
                                                                                                                                                                                                               YES
                                                          ♦ BETA-BLOCKER (IF CAD)
                                                                                                                                                                                                               NO:       CI        NT       $      RF       DA       IA

                                                          GENERAL REVIEW & ADJUST PRN                                                                                                                          REVIEWED                   ADJUSTED

                                                                                  LDL                                                                                                                      ENTER VALUE
                                                          Fasting lipid profile
  3-6 mos (CAD)




                                                                                  Target < 2.5 mmol/L                                                                                                      DATE OF TEST
                                                           (High-risk targets)
   Annually OR

                                        DYSLIPIDEMIA




                                                                                                                                                                                                           ENTER VALUE
                                                                                  ♦RATIO                      TOTAL CHOL
                                                                                                                                                                                                           DATE OF TEST
                                                                                  (TOTAL CHOL/HDL)
                                                                                  TARGET RATIO < 4.0                                                                                                       ENTER VALUE
                                                                                                              HDL
                                                                                                                                                                                                           DATE OF TEST
                                                                                  LIPID RISK                                                                                                                   MODERATE                         HIGH

                                                           METER/LAB COMPARISON
                                        FBG




                                                                                                                                                                                                               COMPLETED
                                                           (Optimally, this is based on fasting glucose)
     ANNUALLY AND/OR OTHERWISE NOTED




                                                           DILATED EYE EXAM                                                                                                                                DATE                             IA
                                        EYE




                                                           Ophthalmologist, optometrist, retinal photo                                                                                                       OPHTHALM     OPTOM   RETIN PHOTO
                                                                                    ♦ MICROALBUMIN SCREEN                                                                                                  ENTER              NEG
                                                          Screen for




                                                                                                                                                                                                                        OR                  IA
                                                           Nephro-
                                        RENAL




                                                                                    (<2.0 M: <2.8 F) (Albumin:creatinine                                                                                   VALUE              POS
                                                            pathy




                                                                                    KIDNEY FUNCTION estimated CrCl                                                                                         SERUM CREATININE     μmol/L
                                                                                    mL/min (Cockroft-Gault formula)                                                                                        DATE OF TEST
                                                           LOWER EXTREMITY EXAM
                                                                                                                                                                                                               REVIEWED              IA
                                       NEURO-
                                       PATHY




                                                           Check for peripheral anesthesia
                                                           HISTORY AND PHYSICAL: Check for pain,
                                                                                                                                                                                                               REVIEWED
                                                           erectile dysfunction, gastrointestinal disturbance
                                                           ASSESS & DISCUSS SELF-MANAGEMENT                                                                                                                    REVIEWED
                                                           GOALS
                                                          ANNUAL INFLUENZA VACCINE                                                                                                                             COMPLETED DATE                                         CI
                                        OTHER




                                                          PNEUMOCOCCAL VACCINE                                                                                                                                 COMPLETED DATE                                         CI
                                                          ♦ REFERRAL TO DIABETES EDUCATION,                                                                                                                    YES
                                                          CARDIAC REHAB, OR OTHER                                                                                                                              NO:     NP          TRP      $       RF        DA       IA
                                                                                     CI – contraindicated NT – not tolerated $ – financial barrier RF – patient refused NP – no program available IA – Inappropriate DA – Didn’t Ask TRP– transportation barrier
Adapted from BCMA Collaborative Flowsheet                                                                                                                                                           FOR COMMENTS SEE NEXT PAGE                                Nov 8/06
DIABETES (+/- coronary artery disease)
COLLABORATIVE FLOW SHEET/ ENCOUNTER FORM
  ♦ PATIENT NAME

  ♦ HSN # (OR OTHER UNIQUE PATIENT ID)           ♦ GENDER           Male
                                                    Female   Undifferentiated

  ♦ PHONE (INCLUDE AREA CODE)               ♦ BIRTHDATE (DD-MMM-YYYY)


  CHART NUMBER                   PRACTICE NAME

  ♦ PROVIDER NAME                                PROVIDER ID # (MSP #)




  COMMENTS




Adapted from BCMA Collaborative Flowsheet                                       Nov 8/06

More Related Content

What's hot

Role of pharmacist in pharmacovigilance field
Role of pharmacist in pharmacovigilance fieldRole of pharmacist in pharmacovigilance field
Role of pharmacist in pharmacovigilance field
Sollers College
 
Chapter-1; Bioassay (Part-3).pptx
Chapter-1; Bioassay (Part-3).pptxChapter-1; Bioassay (Part-3).pptx
Chapter-1; Bioassay (Part-3).pptx
AbdulWahid922079
 
PHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTS
PHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTSPHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTS
PHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTS
Ludy Mae Nalzaro,BSM,BSN,MN
 
Antihyperlipidemic agents
Antihyperlipidemic agentsAntihyperlipidemic agents
Antihyperlipidemic agents
nehar nehar
 
Neuroleptics & Anxiolytics (Abstract)
Neuroleptics & Anxiolytics (Abstract)Neuroleptics & Anxiolytics (Abstract)
Neuroleptics & Anxiolytics (Abstract)
Eneutron
 
co transmission
 co transmission co transmission
co transmission
veluru hari
 

What's hot (6)

Role of pharmacist in pharmacovigilance field
Role of pharmacist in pharmacovigilance fieldRole of pharmacist in pharmacovigilance field
Role of pharmacist in pharmacovigilance field
 
Chapter-1; Bioassay (Part-3).pptx
Chapter-1; Bioassay (Part-3).pptxChapter-1; Bioassay (Part-3).pptx
Chapter-1; Bioassay (Part-3).pptx
 
PHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTS
PHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTSPHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTS
PHARMA-ADRENERGIC AGONIST, ANTAGONIST, CHOLINERGIC AND ANTICHOLINERGIC AGENTS
 
Antihyperlipidemic agents
Antihyperlipidemic agentsAntihyperlipidemic agents
Antihyperlipidemic agents
 
Neuroleptics & Anxiolytics (Abstract)
Neuroleptics & Anxiolytics (Abstract)Neuroleptics & Anxiolytics (Abstract)
Neuroleptics & Anxiolytics (Abstract)
 
co transmission
 co transmission co transmission
co transmission
 

More from primary

Waves Combined Fht By Size S Ont1
Waves Combined Fht By Size S Ont1Waves Combined Fht By Size S Ont1
Waves Combined Fht By Size S Ont1
primary
 
Waves Combined Fht By Size N Ont1
Waves Combined Fht By Size N Ont1Waves Combined Fht By Size N Ont1
Waves Combined Fht By Size N Ont1
primary
 
Waittimes
WaittimesWaittimes
Waittimes
primary
 
Usingstoriestoguideaction
UsingstoriestoguideactionUsingstoriestoguideaction
Usingstoriestoguideaction
primary
 
Tips Tools Reg Diet
Tips Tools Reg DietTips Tools Reg Diet
Tips Tools Reg Diet
primary
 
Tobacco,%20alcohol%20and%20abuse%20screening%20tool
Tobacco,%20alcohol%20and%20abuse%20screening%20toolTobacco,%20alcohol%20and%20abuse%20screening%20tool
Tobacco,%20alcohol%20and%20abuse%20screening%20tool
primary
 
The Sk Action Plan For Primary Health Care
The Sk Action Plan For Primary Health CareThe Sk Action Plan For Primary Health Care
The Sk Action Plan For Primary Health Care
primary
 
The Role And Value Of Primary Care Practice
The Role And Value Of Primary Care PracticeThe Role And Value Of Primary Care Practice
The Role And Value Of Primary Care Practice
primary
 
The Nb Community Health Centers Framework
The Nb Community Health Centers FrameworkThe Nb Community Health Centers Framework
The Nb Community Health Centers Frameworkprimary
 
The Model For Improvement
The Model For ImprovementThe Model For Improvement
The Model For Improvement
primary
 
Teamworking
TeamworkingTeamworking
Teamworking
primary
 
Strategies For Patient Flow
Strategies For Patient FlowStrategies For Patient Flow
Strategies For Patient Flow
primary
 
Snap%2 B Framework%2 Bfor%2 B General%2 B Practice
Snap%2 B Framework%2 Bfor%2 B General%2 B PracticeSnap%2 B Framework%2 Bfor%2 B General%2 B Practice
Snap%2 B Framework%2 Bfor%2 B General%2 B Practice
primary
 
Smithermans Vision 2004
Smithermans Vision 2004Smithermans Vision 2004
Smithermans Vision 2004
primary
 
Sept%20 Cdmc%20 Links%20 Update
Sept%20 Cdmc%20 Links%20 UpdateSept%20 Cdmc%20 Links%20 Update
Sept%20 Cdmc%20 Links%20 Update
primary
 
Role Of Rd In Phc
Role Of Rd In PhcRole Of Rd In Phc
Role Of Rd In Phc
primary
 
Rg0035 A Guideto Service Improvement Nhs Scotland
Rg0035 A Guideto Service Improvement Nhs ScotlandRg0035 A Guideto Service Improvement Nhs Scotland
Rg0035 A Guideto Service Improvement Nhs Scotland
primary
 
Role Of Dieticians
Role Of DieticiansRole Of Dieticians
Role Of Dieticians
primary
 
Relationship%20 Breakdown
Relationship%20 BreakdownRelationship%20 Breakdown
Relationship%20 Breakdown
primary
 
Rethinking%20 Organizational%20 Change%202
Rethinking%20 Organizational%20 Change%202Rethinking%20 Organizational%20 Change%202
Rethinking%20 Organizational%20 Change%202
primary
 

More from primary (20)

Waves Combined Fht By Size S Ont1
Waves Combined Fht By Size S Ont1Waves Combined Fht By Size S Ont1
Waves Combined Fht By Size S Ont1
 
Waves Combined Fht By Size N Ont1
Waves Combined Fht By Size N Ont1Waves Combined Fht By Size N Ont1
Waves Combined Fht By Size N Ont1
 
Waittimes
WaittimesWaittimes
Waittimes
 
Usingstoriestoguideaction
UsingstoriestoguideactionUsingstoriestoguideaction
Usingstoriestoguideaction
 
Tips Tools Reg Diet
Tips Tools Reg DietTips Tools Reg Diet
Tips Tools Reg Diet
 
Tobacco,%20alcohol%20and%20abuse%20screening%20tool
Tobacco,%20alcohol%20and%20abuse%20screening%20toolTobacco,%20alcohol%20and%20abuse%20screening%20tool
Tobacco,%20alcohol%20and%20abuse%20screening%20tool
 
The Sk Action Plan For Primary Health Care
The Sk Action Plan For Primary Health CareThe Sk Action Plan For Primary Health Care
The Sk Action Plan For Primary Health Care
 
The Role And Value Of Primary Care Practice
The Role And Value Of Primary Care PracticeThe Role And Value Of Primary Care Practice
The Role And Value Of Primary Care Practice
 
The Nb Community Health Centers Framework
The Nb Community Health Centers FrameworkThe Nb Community Health Centers Framework
The Nb Community Health Centers Framework
 
The Model For Improvement
The Model For ImprovementThe Model For Improvement
The Model For Improvement
 
Teamworking
TeamworkingTeamworking
Teamworking
 
Strategies For Patient Flow
Strategies For Patient FlowStrategies For Patient Flow
Strategies For Patient Flow
 
Snap%2 B Framework%2 Bfor%2 B General%2 B Practice
Snap%2 B Framework%2 Bfor%2 B General%2 B PracticeSnap%2 B Framework%2 Bfor%2 B General%2 B Practice
Snap%2 B Framework%2 Bfor%2 B General%2 B Practice
 
Smithermans Vision 2004
Smithermans Vision 2004Smithermans Vision 2004
Smithermans Vision 2004
 
Sept%20 Cdmc%20 Links%20 Update
Sept%20 Cdmc%20 Links%20 UpdateSept%20 Cdmc%20 Links%20 Update
Sept%20 Cdmc%20 Links%20 Update
 
Role Of Rd In Phc
Role Of Rd In PhcRole Of Rd In Phc
Role Of Rd In Phc
 
Rg0035 A Guideto Service Improvement Nhs Scotland
Rg0035 A Guideto Service Improvement Nhs ScotlandRg0035 A Guideto Service Improvement Nhs Scotland
Rg0035 A Guideto Service Improvement Nhs Scotland
 
Role Of Dieticians
Role Of DieticiansRole Of Dieticians
Role Of Dieticians
 
Relationship%20 Breakdown
Relationship%20 BreakdownRelationship%20 Breakdown
Relationship%20 Breakdown
 
Rethinking%20 Organizational%20 Change%202
Rethinking%20 Organizational%20 Change%202Rethinking%20 Organizational%20 Change%202
Rethinking%20 Organizational%20 Change%202
 

Recently uploaded

Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 

Recently uploaded (20)

Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 

Diabetes Flowsheet

  • 1. DIABETES (+/- coronary artery disease) COLLABORATIVE FLOW SHEET/ ENCOUNTER FORM ♦ PATIENT NAME PAST HISTORY ALCOHOL OVERUSE ARRHYTHMIA: ATRIAL FIB ARRHYTHMIA: OTHER ♦ HSN # (OR OTHER UNIQUE PATIENT ID) ♦ GENDER Male ARTHRITIS CANCER CARDIOMYOPATHY Female Undifferentiated CHF CHRONIC LUNG DIS. DEPRESSION ♦ PHONE (INCLUDE AREA CODE) ♦ BIRTHDATE (DD-MMM-YYYY) HYPERTENSION LIPID ABNORMALITY LIVER DYSFUNCTION OBESITY PERIPH. VASC. DIS. RENAL DYSFUNCTION CHART NUMBER PRACTICE NAME STROKE/TIA SUBSTANCE ABUSE VALVULAR HD ♦ PROVIDER NAME PROVIDER ID # (MSP #) ♦ DIABETES YEAR OF DX: TYPE 1 TYPE 2 OTHER ♦ CAD ___CHRONIC ANGINA, YEAR OF DX: ___MI, YEAR OF DX: ___CABG, DATE: FRAMINGHAM RISK ___ ___ACS/UNSTABLE ANGINA , YEAR OF DX: ___PCI/Stent. DATE: SCORE DIAGNOSTIC/ CLINICAL DATA, BY DATE NEW DATA √ = RECALL REVIEW ♦ = MANDATORY MOST RECENT DATA FIELDS DATE OF VISIT: URGENT CARE for DM &/or CAD None (enter # of urgent visits) ER/hospitalizations since last planned visit CLINICAL STATUS REVIEWED BLOOD GLUCOSE RECORDS REVIEWED GLYCEMIC CONTROL ♦ A1C EVERY 3 MONTHS: ENTER VALUE TARGET ≤ 7.0% DATE OF TEST DIABETES MEDICATIONS/INSULIN REVIEWED ADJUSTED Review & adjust PRN SYMPTOMS STABLE: angina, palpitations, N/A STABLE NOT STABLE CAD shortness of breath, swelling, dizziness angina palp. SOB swelling dizzy ♦ BLOOD PRESSURE ENTER VALUE HTN TARGET ≤130/80 DATE OF TEST 3 TO 6 MONTHS TARGET BODY MASS INDEX (BMI) LBS KG 18.5 – 24.9 Height: Enter weight (LBS or KG) LIFESTYLE nd ♦ SMOKING Current 2 Hand Past Never AEROBIC EXERCISE YES NO IA > 30 minutes most days, moderate intensity OTHER LIFESTYLE FACTORS REVIEWED Stress, diet, alcohol YES ♦ ANTI-PLATELET (ASA/OTHER) NO: CI NT $ RF DA IA YES ♦ ACE OR ARB MEDICATIONS NO: CI NT $ RF DA IA YES ♦ STATIN NO: CI NT $ RF DA IA YES ♦ BETA-BLOCKER (IF CAD) NO: CI NT $ RF DA IA GENERAL REVIEW & ADJUST PRN REVIEWED ADJUSTED LDL ENTER VALUE Fasting lipid profile 3-6 mos (CAD) Target < 2.5 mmol/L DATE OF TEST (High-risk targets) Annually OR DYSLIPIDEMIA ENTER VALUE ♦RATIO TOTAL CHOL DATE OF TEST (TOTAL CHOL/HDL) TARGET RATIO < 4.0 ENTER VALUE HDL DATE OF TEST LIPID RISK MODERATE HIGH METER/LAB COMPARISON FBG COMPLETED (Optimally, this is based on fasting glucose) ANNUALLY AND/OR OTHERWISE NOTED DILATED EYE EXAM DATE IA EYE Ophthalmologist, optometrist, retinal photo OPHTHALM OPTOM RETIN PHOTO ♦ MICROALBUMIN SCREEN ENTER NEG Screen for OR IA Nephro- RENAL (<2.0 M: <2.8 F) (Albumin:creatinine VALUE POS pathy KIDNEY FUNCTION estimated CrCl SERUM CREATININE μmol/L mL/min (Cockroft-Gault formula) DATE OF TEST LOWER EXTREMITY EXAM REVIEWED IA NEURO- PATHY Check for peripheral anesthesia HISTORY AND PHYSICAL: Check for pain, REVIEWED erectile dysfunction, gastrointestinal disturbance ASSESS & DISCUSS SELF-MANAGEMENT REVIEWED GOALS ANNUAL INFLUENZA VACCINE COMPLETED DATE CI OTHER PNEUMOCOCCAL VACCINE COMPLETED DATE CI ♦ REFERRAL TO DIABETES EDUCATION, YES CARDIAC REHAB, OR OTHER NO: NP TRP $ RF DA IA CI – contraindicated NT – not tolerated $ – financial barrier RF – patient refused NP – no program available IA – Inappropriate DA – Didn’t Ask TRP– transportation barrier Adapted from BCMA Collaborative Flowsheet FOR COMMENTS SEE NEXT PAGE Nov 8/06
  • 2. DIABETES (+/- coronary artery disease) COLLABORATIVE FLOW SHEET/ ENCOUNTER FORM ♦ PATIENT NAME ♦ HSN # (OR OTHER UNIQUE PATIENT ID) ♦ GENDER Male Female Undifferentiated ♦ PHONE (INCLUDE AREA CODE) ♦ BIRTHDATE (DD-MMM-YYYY) CHART NUMBER PRACTICE NAME ♦ PROVIDER NAME PROVIDER ID # (MSP #) COMMENTS Adapted from BCMA Collaborative Flowsheet Nov 8/06